|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
This site will provide you with information about Pharma Industry Finland and give you facts and figures about the pharmaceutical industry.
You can read about the industry's current issues and have a look at our English publications.
Current issues
| [08/02/2010] Pharma Industry Finland (PIF) greets new Director of Pharmaceuticals Pricing Board: » Pharma Industry Finland congratulates the new Director of Pharmaceuticals Pricing Board for the new position, wishing him the best of success in his work. |
| [09/11/2009] Pharma Industry Finland: Fimea plays an important role for the development of the entire health care sector » Starting its work as of the beginning of November, the Finnish Medicines Agency Fimea plays an important role for the entire health care sector. Besides the pharmaceutical regulation tasks, Fimea is also responsible for new research and development functions which are the object of many expectations. |
| [09/11/2009] PIF comments on the appointment of Director General for Finnish Medicines Agency Fimea: we look forward to versatile co-operation » Pharma Industry Finland congratulates Sinikka Rajaniemi who has been appointed as the Director General of Fimea, the Finnish Medicines Agency, hoping that under its Director General, Fimea would engage in an open dialogue with its stakeholders. |
Basic mission of PIF
Basic mission of Pharma Industry Finland is to build a predictable, transparent and interactive operating environment in Finland in the European context.
Pharma Industry Finland promotes the health of Finnish people, the offer of therapies that best suit the individuals as well as their adherence to treatment with the aim of optimising the overall healthcare expenditure.
PIF represents the whole industrial lifecycle of medicines, extending from early research phases to developing original, innovative medicines, generics, OTC and veterinary medicines. The basis of the PIF membership is the commitment to these principles.
Our ethical principles are:
- Impeccable and stable management of pharmacovigilance issues.
- Dissemination of reliable and fact-based information.
- Responsible and persistent operation on the Finnish market.
- Credible operation from all major stakeholders' perspective.
- Commitment to themes jointly agreed within PIF, also in the member company operations and communications.
